ALSO NOTED: Ariad secures financing; Akzo to proceed with spinoff; Halozyme touts data; and much more...

> Ariad Pharmaceuticals has secured a financing commitment worth up to $50 million. "We are currently negotiating detailed terms with multiple pharmaceutical companies for a partnership to develop and commercialize AP23573 in a broad range of oncology indications. We expect to complete the partnership agreement by early second quarter 2007," said CEO Harvey J. Berger. Release | Report

> Akzo Nobel says it will go ahead with plans to spin off its Organon BioSciences division in an IPO. Report

> Halozyme Therapeutics is touting data from a Phase IIb trial of morphine given in combination with Hylenex. Report

> An international team of scientists including Professor Philippe Froguel of Imperial College, London has identified a group of genetic variants that they believe can flag the risk of type 2 diabetes in 70 percent of all cases. Report

> Arizona State University's Biodesign Institute is teaming with researchers at the Mayo Clinic to develop new cancer vaccines. Report

> Stem cells take center stage in San Diego summit. Report

> Scientists sniff out method to make artificial nose. Report

And Finally… Eli Lilly won an injunction against the further release of documents regarding its controversial drug Zyprexa. These are the same documents used by The New York Times in its expose on Zyprexa's lethal side effects. Report

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.